
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
European Union-Both prescription and over-the-counter (OTC) industry sectors have welcomed the long-awaited proposals to overhaul EU pharma legislation.
about 25 years ago
Profits and Promotion Under Attackabout 25 years ago
New Playing Fieldsabout 25 years ago
Inefficiencies: Cutting Through the Jungleabout 25 years ago
Flexing Their Budgets: Big Pharma Spend Trendsabout 25 years ago
Media Mix Town Meeting 2001: Much Ado About Media





